Cover Image

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Soleimani Dodaran, Maryam (Author) , Borgoni, Simone (Author) , Sofyali, Emre (Author) , Verschure, Pernette J. (Author) , Wiemann, Stefan (Author) , Moerland, Perry D. (Author) , van Kampen, Antoine H. C. (Author)
Format: Article (Journal)
Language:English
Published: 19 July 2020
In: BMC cancer
Year: 2020, Volume: 20
ISSN:1471-2407
DOI:10.1186/s12885-020-07100-z
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-07100-z
Get full text
Author Notes:Maryam Soleimani Dodaran, Simone Borgoni, Emre Sofyalı, Pernette J. Verschure, Stefan Wiemann, Perry D. Moerland and Antoine H.C. van Kampen
Description
Summary:Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the methylation profile have been implicated as one of the mechanisms through which therapy resistance develops. Therefore, we aimed to identify methylation loci associated with endocrine therapy resistance.
Item Description:Gesehen am 01.09.2020
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-020-07100-z

Similar Items